-
Geriatric assessment in Acute Myeloid Leukemia (AML). Acta Haematol. (IF 2.4) Pub Date : 2023-11-30 Justin D Woods,Heidi D Klepin
Background Acute myeloid leukemia (AML) is a heterogenous disease that affects mostly older adults with varying baseline health and functional status. Treatment options have expanded for older adults ranging from less intensive chronic therapies to intensive induction strategies with curative intent. Despite this, outcomes remain poor with advancing age due to underlying disease biology and variability
-
Test then erase? Current status and future opportunities for Measurable Residual Disease testing in Acute Myeloid Leukemia. Acta Haematol. (IF 2.4) Pub Date : 2023-11-30 Amanda L Blackmon,Christopher S Hourigan
BACKGROUND Measurable residual disease (MRD) test positivity during and after treatment in patients with acute myeloid leukemia (AML) has been associated with higher rates of relapse and worse overall survival. Current approaches for MRD testing are not standardized leading to inconsistent results and poor prognostication of disease. Pertinent studies evaluating AML MRD testing at specific times points
-
Untangling Complexities of Acute Myeloid Leukemia Review Series. Acta Haematol. (IF 2.4) Pub Date : 2023-11-30 Shai Shimony,Richard M Stone
-
Optimal post-remission consolidation therapy in patients with AML. Acta Haematol. (IF 2.4) Pub Date : 2023-11-26 Carlos Jimenez-Chillon,Richard Dillon,Nigel Russell
BACKGROUND Despite recent advances, 40-85% of patients with acute myeloid leukemia (AML) achieve complete remission after intensive chemotherapy. However, without optimal treatment after remission, the risk of relapse remains high. SUMMARY A variable number of consolidation cycles consisting of intermediate doses of cytarabine are the most commonly used regimens in low-intermediate risk AML, while
-
Long-term Clinical Outcomes of Optimizing Combination Therapy for Primary Pulmonary Mucosa-associated Lymphoid Tissue Lymphoma: A Retrospective Study. Acta Haematol. (IF 2.4) Pub Date : 2023-11-24 Gi-June Min,Chin Kook Rhee,Tong Yoon Kim,Young-Woo Jeon,Joo Hyun O,Byung-Ock Choi,Gyeongsin Park,Seok-Goo Cho
INTRODUCTION Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma progresses with advancing disease stage. However, no standard treatment approach has been established. This single-center retrospective study evaluated clinical and radiological characteristics, treatment modalities, and long-term prognosis of pulmonary MALT lymphoma. METHODS The study included 42 patients diagnosed with pulmonary
-
In Memoriam: Isaac Ben-Bassat (1937-2023) A Lifelong Legacy in Hematology. Acta Haematol. (IF 2.4) Pub Date : 2023-11-24 Pia Raanani
-
Complete response to donor lymphocyte infusion for primary hemophagocytic lymphohistiocytosis relapse after allogeneic hematopoietic cell transplantation. Acta Haematol. (IF 2.4) Pub Date : 2023-11-23 Rutvij A Khanolkar,Nathan Kuehne,Jan Storek
Primary hemophagocytic lymphohistiocytosis (HLH) is a hyper-inflammatory disorder characterized by dysregulation of inflammatory cells and cytokine signalling. Although first-line treatment consisting of immunosuppressive therapy and allogeneic hematopoietic cell transplantation (HCT) is often curative, it remains unknown whether any effective therapies exist for disease relapse/progression after HCT
-
Fluoroquinolone Prophylaxis During Conventional Chemotherapy or Hematopoietic Stem Cell Transplantation for Acute Leukemia - Pros and Cons. Acta Haematol. (IF 2.4) Pub Date : 2023-11-21 Tomer Hoffman,Alaa Atamna,Vladislav Litchevsky,Irina Amitai,Dafna Yahav
Background Prophylaxis with fluoroquinolones (FQ) is commonly used in patients with acute leukemia (AL) during neutropenia. This practice is supported by an older meta-analysis reporting reduced mortality using FQ prophylaxis. Later meta-analyses have failed to reproduce this finding, presumably due to higher background FQ resistance rates limiting their effectiveness. Summary This article reviews
-
Acute febrile neutrophilic dermatosis (Sweet syndrome) in acute myeloid leukemia patients: a 28-year institutional experience. Acta Haematol. (IF 2.4) Pub Date : 2023-11-21 Emily A Cowen,Dulce M Barrios,Melissa P Pulitzer,Andrea P Moy,Stephen W Dusza,Susan De Wolf,Mark B Geyer,Alina Markova
INTRODUCTION Sweet syndrome (SS) is well-known to be associated with underlying hematologic malignancies. The incidence and qualities of SS among novel targeted therapies for acute myeloid leukemia (AML) have not yet been described. METHODS Through retrospective review of 19432 patients diagnosed with acute/chronic leukemia or myelodysplastic syndromes/ myeloproliferative neoplasms (MDS+/-MPN) over
-
The role of hepcidin and an oral iron absorption test in identifying the root cause of iron-restricted anemia. Acta Haematol. (IF 2.4) Pub Date : 2023-11-16 Roberta Loveikyte,Yascha van den Berg,Andrea van der Meulen-de Jong,Lodewijk Thomas Vlasveld
INTRODUCTION Traditional iron parameters often fail to distinguish the cause of iron-restricted anemia in patients without an obvious underlying cause. We evaluated whether an oral iron absorption test (OIAT) and hepcidin measurement could be useful diagnostic tests in these patients. METHODS We retrospectively analyzed data extracted from medical records of all patients who underwent an OIAT and hepcidin
-
Tumor lysis syndrome is associated with worse outcomes in adult patients with acute lymphoblastic leukemia. Acta Haematol. (IF 2.4) Pub Date : 2023-11-14 Fausto A Rios-Olais,Fernando Gil-Lopez,Analy Mora-Cañas,Roberta Demichelis-Gómez
INTRODUCTION Tumor lysis syndrome (TLS) occurs frequently during induction therapy for acute lymphoblastic leukemia (ALL). Patients are categorized into intermediate or high risk based on lactate dehydrogenase (LDH) value and white blood cell (WBC) count according to an expert panel, although no effort has been made to analyze TLS in ALL and its potential consequences. METHODS We retrospectively analyzed
-
A Rare Clinical Case of Secondary Central Nervous System Involvement without Transformation in Hairy Cell Leukemia: Case Report and Literature Review. Acta Haematol. (IF 2.4) Pub Date : 2023-11-10 Kenichi Ito,Kunihiko Harada,Yoshihito Uchino,Kazuhiko Hirano,Naohiro Sekiguchi
Introduction Hairy cell leukemia (HCL) is an indolent B-cell lymphoma characterized by a specific genetic mutation, BRAF V600E, which affects the specific morphology and oncogenesis. For HCL, few reports regarding secondary central nervous system involvement (SCNSI) are available. Herein, we present the case of an 80-year-old woman who had a relapse of HCL with SCNSI. Case presentation The diagnosis
-
Shikonin exerts an anti-leukemia effect against FLT3-ITD mutated acute myeloid leukemia cells via targeting FLT3 tyrosine kinase and its downstream pathways. Acta Haematol. (IF 2.4) Pub Date : 2023-11-03 Mu-Nan Zhao,Long Su,Fei Song,Zhi-Feng Wei,Tian-Xue Qin,Yun-Wei Zhang,Wei Li,Su-Jun Gao
INTRODUCTION Acute myeloid leukemia (AML) with internal tandem duplication (ITD) mutations in Fms-like tyrosine kinase 3 (FLT3) has an unfavorable prognosis. Recently, using newly emerging inhibitors of FLT3 has led to improved outcomes of patients with FLT3-ITD mutations. However, drug resistance and relapse continue to be significant challenges in the treatment of patients with FLT3-ITD mutations
-
Non-immunotherapy approaches for Relapsed or Refractory AML: an update for 2024. Acta Haematol. (IF 2.4) Pub Date : 2023-10-31 Shira Buchrits,Ofir Wolach
BACKGROUND Relapsed or refractory (R/R) acute myeloid leukemia (AML) is a challenging, high-risk, clinical scenario with a dismal outcome. Recent insights on the genetic, epigenetic, and metabolic events that drive clonal progression and the advent of novel therapies resulted in the incorporation of several new targeted therapies, alone or in combination, in the R/R setting with the aim of improving
-
Importance of MRD in the era of targeted therapies in CLL. Acta Haematol. (IF 2.4) Pub Date : 2023-10-30 Othman Al Sawaf
The level of Minimal residual disease (MRD), often binarized into detectable or undetectable MRD according to certain thresholds, is strongly associated with long-term outcomes after chemo- and chemoimmunotherapy. Driven by our improved understanding of the biology of CLL, the recent decade has shown a shift from chemotherapy-based regimens to regimens based on targeted agents that exploit distinct
-
Frontline therapy in Chronic Lymphocytic Leukemia. Acta Haematol. (IF 2.4) Pub Date : 2023-10-27 Miguel Arguello-Tomas,Nil Albiol,Carol Moreno
The treatment landscape of chronic lymphocytic leukemia (CLL) has tremendously evolved in the last decades thanks to the introduction of more effective therapies. Front-line therapy for patients with CLL includes chemoimmunotherapy (CIT) and pathway inhibitors (PI) (i.e., Bruton tyrosine kinase inhibitors and BCL2 inhibitors); the latter have proved to be more effective than CIT mainly in patients
-
Addendum to the German Consensus Recommendations on Ponatinib in the Treatment of Chronic Myeloid Leukemia. Acta Haematol. (IF 2.4) Pub Date : 2023-10-17 Susanne Saussele,Paul La Rosée,Alexander Kiani,Wilhelm Haverkamp,Kathleen Jentsch-Ullrich,Frank Stegelmann,Christina Rieger,Cornelius F Waller,Georg-Nikolaus Franke,Christian Junghanss,Rudolf Kirchmair,Markus Theurl,Philipp le Coutre
BACKGROUND Based on the new data from the primary analysis of the OPTIC (Optimizing Ponatinib Treatment in CP-CML) trial on dose optimization of ponatinib in patients with chronic phase (CP)-CML, the German consensus paper on ponatinib published in 2020 (Saussele S et al., Acta Haematol. 2020) has been updated in this addendum. SUMMARY Focus is on the update of efficacy and safety of ponatinib, reflecting
-
"Don't add fuel to the fire"- Hyperhemolysis Syndrome in a pregnant woman with compound Sickle cell disease/ß0-thalassemia - Case report and review of the literature. Acta Haematol. (IF 2.4) Pub Date : 2023-10-13 Anke Rihsling,Helena Simeunovic,Sergio Sanchez,Christine Henny,Sofia Lejon Crottet,Behrouz Mansouri Teleghani,Michael Daskalakis,Martin Müller,Luigi Raio,Alicia Rovó
Hyperhemolysis Syndrome (HHS) is a rare and severe post-transfusion complication characterized by the destruction of both recipient and donor red blood cells (RBC). The underlying mechanism of HHS is not fully understood and proper management can be difficult. Furthermore, there are few reports regarding HHS in pregnancy. We report on the development and management of HHS in a pregnant woman with known
-
Cellular therapy in chronic lymphocytic leukemia: have we advanced in the last decade? Acta Haematol. (IF 2.4) Pub Date : 2023-10-09 Ofrat Beyar Katz,Dana Yehudai-Ofir,Tsila Zuckerman
BACKGROUND Chronic lymphocytic leukemia (CLL) is a heterogeneous B-cell malignancy, affecting mainly older adults. Despite the recent introduction of multiple targeted agents, CLL remains an incurable disease. Cellular therapy is a promptly evolving area that has developed over the last decades from such standard of care as hematopoietic cell transplantation (HCT) to the novel treatment modalities
-
Clinico-Radio-Pathologic Correlation of Leukostasis in Acute Myeloid Leukemia with FLT3 Mutation. Acta Haematol. (IF 2.4) Pub Date : 2023-10-03 Elisa Bello,Haihui Liao,Shyam A Patel
The systemic complications of acute hematologic emergencies account for the high mortality rates seen during inpatient management. Perhaps the most challenging diagnostic entity among all hematologic emergencies is leukostasis. In acute myeloid leukemia, myeloid blasts are often highly adherent to the endothelial vasculature, and high peripheral blood blast count in excess of 100,000 cells per microliter
-
Fostamatinib or Thrombopoietic Receptor Agonists for the Treatment of Chronic Immune Thrombocytopenia in Adult Patients: A Real-World Assessment of Safety, Effectiveness and Cost. Acta Haematol. (IF 2.4) Pub Date : 2023-09-29 George Dranitsaris,Aaron Peevyhouse,Tiffany Wood,Yuliya Kreychman,Heather Neuhalfen,Mehdi Moezi
INTRODUCTION Chronic immune thrombocytopenia purpura (ITP) in adults is a serious autoimmune disease in which platelets are prematurely destroyed, leaving the patient vulnerable to bruising and bleeding. Initial treatment is with corticosteroids. In patients who become resistant or intolerant to corticosteroids, the thrombopoietic agents (TPOs), consisting of romiplostim (ROM), eltrombopag (ELT) and
-
Machine learning for the prediction of survival post-allogeneic hematopoietic cell transplantation: A single-center experience. Acta Haematol. (IF 2.4) Pub Date : 2023-09-28 Hamed Shourabizadeh,Dionne M Aleman,Louis-Martin Rousseau,Arjun D Law,Auro Viswabandya,Fotios V Michelis
INTRODUCTION Prediction of outcomes following allogeneic hematopoietic cell transplantation (HCT) remains a major challenge. Machine learning (ML) is a computational procedure that may facilitate the generation of HCT prediction models. We sought to investigate the prognostic potential of multiple ML algorithms when applied to a large single-center allogeneic HCT database. METHODS Our registry included
-
Intermittent high-dose glucocorticoid treatment does not cause adrenal insufficiency in patients with diffuse large B-cell lymphoma - a prospective study. Acta Haematol. (IF 2.4) Pub Date : 2023-09-27 Margret Jona Einarsdottir,Hallgerdur L Kristjansdottir,Ragnhildur Bergthorsdottir,Gudmundur Johannsson,Penelope Trimpou,Catharina Lewerin,Oskar Ragnarsson
Glucocorticoid (GC) treatment suppresses the hypothalamic-pituitary-adrenal axis and can cause GC-induced adrenal insufficiency. In this study we investigated the incidence of GC-induced adrenal insufficiency in patients receiving intermittent short-term high-dose oral GC treatment for newly diagnosed diffuse large B-cell lymphoma. Cosyntropin stimulation test was used to assess adrenal function at
-
Evidence-based Management of Chronic Lymphocytic Leukemia: Consensus Statements from the Gulf Region. Acta Haematol. (IF 2.4) Pub Date : 2023-09-26 Salem H Alshemmari,Mustaqeem A Siddiqui,Ramesh Pandita,Hani Y Osman,Honar Cherif,Susan O'Brien,Mahmoud Marashi,Khalil Al Farsi
INTRODUCTION Despite recent advances in diagnosis, prognostication, and treatment options, chronic lymphocytic leukemia (CLL) is still a largely incurable disease. New concepts on diagnosis, staging, treatment, and follow-up on CLL have been incorporated throughout recent years. The lack of regional consensus guidelines has led to varying practices in the management of patients with CLL in the region
-
Limited efficacy of Venetoclax Combination Regimens in Acute Myeloid Leukemia with Extramedullary Relapse. Acta Haematol. (IF 2.4) Pub Date : 2023-09-26 Soyoung Bae,Seungwon Sa,Silvia Park,Byung-Sik Cho,Hee-Je Kim
The recently approved Bcl-2 inhibitor venetoclax (VEN) has achieved promising outcomes in new and relapsed/refractory (R/R) acute myeloid leukemia (AML). Although its use is not well-established in R/R AML with extramedullary disease (EMD), some reports have shown promising outcomes. We retrospectively analyzed 11 patients of R/R AML with EMD [with (n=4) or without (n=7) concurrent marrow involvement]
-
Exclusion of Acute Myeloid Leukemia Patients with Central Nervous System Involvement from Clinical Trials: An Analysis of the National Institutes of Health Clinical Trials Registry from 2012-2022. Acta Haematol. (IF 2.4) Pub Date : 2023-09-26 Dahniel Sastow,Grace Van Hyfte,Jonathan Feld,Marina Kremyanskaya,John Mascarenhas,Douglas Tremblay
INTRODUCTION Central nervous system (CNS) involvement in acute myeloid leukemia (AML) can be successfully treated with intrathecal chemotherapy and carries debatable prognostic impact. However, patients with CNS involvement are commonly excluded from clinical trials at an unknown rate. We systematically evaluated exclusion criteria of AML clinical trials based on CNS involvement and determined associations
-
Bortezomib and Vorinostat Therapy as Maintenance Therapy Post Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen. Acta Haematol. (IF 2.4) Pub Date : 2023-09-14 Leona A Holmberg,David G Maloney,Laura Connelly-Smith
INTRODUCTION The success of autologous stem cell transplantation (ASCT) for treating non-Hodgkin's lymphoma (NHL) is limited by its high relapse rates. To reduce the risk of relapse, additional maintenance therapy can be added post-transplant. In a non-transplant setting at the time of initiation of this study, both bortezomib and vorinostat had been studied alone or in combination for some NHL histology
-
Cladribine, Cytarabine, And Etoposide (CCE)-Based Regimens Are Safe and Tolerable In Relapsed And Refractory AML Patients. Acta Haematol. (IF 2.4) Pub Date : 2023-09-14 Jose Tinajero,Dat Ngo,Amandeep Salhotra,Paul Koller
Intensive treatment regimens for relapsed/refractory (R/R) acute myeloid leukemia (AML) generally include an anthracycline, cytarabine, with or without a purine analogue. In patients who cannot tolerate an anthracycline due to comorbidities may consider using etoposide. Given the ongoing fludarabine shortage, it has prompted the switch to other purine analogues, such as cladribine, in combination with
-
Prognostic Markers in the Era of Targeted Therapies. Acta Haematol. (IF 2.4) Pub Date : 2023-09-13 Sorang Kang,Inhye E Ahn
Background Small molecules targeting Bruton's tyrosine kinase (BTK) and B-cell lymphoma-2 have become the standard of care for the treatment of chronic lymphocytic leukemia (CLL), replacing chemoimmunotherapy (CIT) in most clinical settings. Ongoing trials explore targeted combinations and minimal residual disease-driven treatment cessation. These dramatic shifts in the current and upcoming treatment
-
CLL - Novel Perspectives - How to Teach an Old Dog New Tricks. Acta Haematol. (IF 2.4) Pub Date : 2023-09-13 Jan Burger,Tamar Tadmor
-
Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years. Acta Haematol. (IF 2.4) Pub Date : 2023-09-12 Lucia Masarova,Prithviraj Bose,Naveen Pemmaraju,Lingsha Zhou,Sherry Pierce,Zeev Estrov,Hagop Kantarjian,Srdan Verstovsek
INTRODUCTION Median duration of therapy with the first JAK1/2 inhibitor ruxolitinib (RUX) approved for patients with intermediate or high- risk myelofibrosis (MF) is about 3 years. METHODS In this retrospective study, we aimed to evaluate clinical features, predictive factors and outcome of patients presenting to our institution who were able to remain on RUX for ≥5 years (n = 73). RESULTS Comparing
-
Immunotherapy for acute myeloid leukemia: current trends, challenges, and strategies. Acta Haematol. (IF 2.4) Pub Date : 2023-09-06 Evan C Chen,Jacqueline S Garcia
BACKGROUND In the past decade, there have been significant breakthroughs in immunotherapies for B-cell lymphoid malignancies and multiple myeloma, but progress has been much less for acute myeloid leukemia (AML). Nevertheless, challenge begets innovation and several therapeutic strategies are under investigation. SUMMARY In this review, we review the state of the art in AML immunotherapy including
-
Accelerated Chronic Lymphocytic Leukemia and Richter Transformation in the Era of Novel Agents. Acta Haematol. (IF 2.4) Pub Date : 2023-09-04 Ilana Levy Yurkovski,Tamar Tadmor
BACKGROUND Tremendous developments in the field of Chronic Lymphocytic leukemia (CLL) in recent years has led to a revolutionary change in the treatment approach, which today is based on targeted treatments with a good response and optimal prognosis. Nevertheless, CLL can present or progress to "accelerated CLL" (A-CLL) or to "Richter transformation" (RT) and these two entities have a more aggressive
-
The effect of iron overload on the mobilization of peripheral blood hematopoietic stem cells in pediatric patients with thalassemia major. Acta Haematol. (IF 2.4) Pub Date : 2023-08-25 Bindanda Mvuama Van Timothee,Jing Du,Yuqiong Ren,Yuelin He,Yongsheng Ruan,Xuan Liu,Libai Chen,Jianyun Wen,Rongfang Ding,Li Yu,Qiujun Liu,Xiaoting Liu,Jianyun Liao,Zhiyong Peng,Xuedong Wu,Chunfu Li,Xiaoqin Feng
INTRODUCTION The purpose of this study was to examine the effect of iron overload on the mobilization of peripheral blood stem cells (PBSCs) in pediatric patients with ꞵ-thalassemia major (TM). METHODS We retrospectively reviewed the records of 226 patients with TM from whom PBSCs were collected. Iron overload was based on serum ferritin level, and liver and cardiac iron overload measured by magnetic
-
AKAP12 and IGFBP4 are prognostic factors for chronic lymphocytic leukemia. Acta Haematol. (IF 2.4) Pub Date : 2023-08-21 Yuye Shi,Xiaohu Xu,Zhengmei He,Hong Tao,Yue Chen,Lijuan Zhang,Shandong Tao,Banghe Ding,Chunling Wang,Liang Yu
INTRODUCTION To develop a prognostic model for chronic lymphocytic leukemia (CLL). METHODS GEO2R was used to retrieve the gene expression data of CLL and normal B cells from the Gene Expression Omnibus (GEO, GSE22529 and GSE50006 datasets) database. Perl (Practical Extraction and Report Language) was used to extract the gene expression and overall survival (OS) data of CLL patients from the CLLE-ES
-
Analysis of hematological indices and splenectomy rates in 2,130 patients with Hemoglobin H diseases or β-thalassemia. Acta Haematol. (IF 2.4) Pub Date : 2023-08-11 Yaoyun Li,Yaqing Zhang,Lang Qin,Hangning Shang,Pingping Li,Bin Xiao,Yuhua Ye,Xiangmin Xu,Xinhua Zhang,Li Wang
Introduction Splenomegaly and hypersplenism are common complications of thalassemia patients due to the excessive clearance of defective red blood cells from the spleen. To date, splenectomy has been considered one of the most effective treatments for splenomegaly, reducing clinical severity among thalassemia patients. Thus, we aim to investigate the differences in splenectomy rates and hematological
-
Sustained Response to Ruxolitinib of Eosinophilia-Associated Myeloproliferative Neoplasm with Translocation t(8;9)(p21;p24). Acta Haematol. (IF 2.4) Pub Date : 2023-08-10 Ping Cai,Suhui Liu,Lijuan Duan,Li Huo,Depei Wu,Suning Chen,Ruyu Yang,Xiaofei Yang
The translocation t(8;9) produces the fusion gene PCM1-JAK2, resulting in the continuous activation of the JAK2 tyrosine kinase. Myelodysplastic/myeloproliferative neoplasms are the most common disease with t(8;9)/PCM1-JAK2. Individuals with this abnormality have similar features, and JAK2 kinase inhibitor (ruxolitinib) is an effective treatment of the condition. The long-term remission results of
-
A case report of Chronic myelogenous leukemia presenting as blastic crisis with a T-cell acute lymphoblastic leukemia phenotype: Awareness of a rare entity. Acta Haematol. (IF 2.4) Pub Date : 2023-08-09 Maria Efstathopoulou,Katerina Zoi,Marina P Siakantaris,Daphne Koumbi,Anna Zannou,Evangelia-Faidra Triantafyllou,Gerassimos Tsourouflis,Eleftheria Lakiotaki,Theodoros Vassilakopoulos,Maria K Angelopoulou
Chronic Myelogenous leukemia at blast crisis with a T-cell phenotype (T-ALL CML-BC ) at diagnosis, without any prior history of CML is extremely rare. After the introduction of TKIs, CML patients have a median survival comparable to general population and accelerated/blast crisis are rarely encountered. Most CML patients (80%) transform into AML and the rest into B-ALL. Anecdotal cases of Ph+ T-ALL
-
The impact of thrombocytopenia and lymphopenia on mortality in patients infected with Influenza virus - a retrospective cohort study. Acta Haematol. (IF 2.4) Pub Date : 2023-08-09 Adi Sherban,Ragda Hussen,Anat Gafter-Gvili,Alla Atamna,Jihad Bishara,Pia Raanani,Kim Ben Tikva Kagan,Tomer Avni
Introduction Influenza virus causes significant global annual morbidity and mortality. Thrombocytopenia is recognized as a poor prognostic factor in sepsis and is associated with mortality, while lymphopenia has been established as a poor prognostic factor in other viral infections. We aimed to assess the incidence of thrombocytopenia and lymphopenia in seasonal influenza and their effect on clinical
-
Consensus statements highlight the need of harmonizing CLL management worldwide. Acta Haematol. (IF 2.4) Pub Date : 2023-08-07 Stefano Molica,Marco Rossi,David Allsup
-
Busulfan for allogeneic hematopoietic stem cell transplantation in children with severe aplastic anemia: A retrospective study. Acta Haematol. (IF 2.4) Pub Date : 2023-07-31 Yingjian Si,Rongmu Luo,Maoquan Qin,Zhenlan Du,Xiaomei Zhang,Ya Wang,Wei Chen,Wenjing Gu,Guosheng Xing,Lingsong Dou,Wei Cao,Zhichun Feng
Introduction This retrospective study aimed to compare a range of conditioning regimens in children with severe aplastic anemia (SAA) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) at the Seventh Medical Center of PLA General Hospital between January 2008 and June 2017. Methods Patients were categorized into the Bu (Bu + Flu + Cy + ATG-F regimen) and control (Flu + Cy + ATG-F)
-
Clinical outcomes of COVID-19 in Mycosis Fungoides and Sezary Syndrome. Acta Haematol. (IF 2.4) Pub Date : 2023-07-29 Ilana Levy Yurkovski,Lior Rokach,Guy Melamed,Hillel Alapi,Sivan Gazit,Tal Patalon,Tamar Tadmor
INTRODUCTION Haemato-oncologic patients are more susceptible to severe infections with SARS-CoV-2. We aimed to assess the clinical outcomes of SARS-CoV-2 infection among patients with Mycosis Fungoides and Sezary Syndrome (MF/SS). METHODS The data was retrieved from anonymized electronic medical records of Maccabi Healthcare Services (MHS), the second-largest healthcare organization in Israel. Patients
-
Immune dysfunction and infection - interaction between CLL and treatment A reflection on current treatment paradigms and unmet needs. Acta Haematol. (IF 2.4) Pub Date : 2023-07-27 Ernesto Gargiulo,Rebecca Svanberg Teglgaard,Tereza Faitová,Carsten Utoft Niemann
Background Chronic lymphocytic leukemia (CLL) is a hematological malignancy characterized by immune dysfunction, which significantly contributes to increased morbidity and mortality due to infections. Summary Advancement in therapeutic strategies based on combination chemoimmunotherapy and targeted treatment have increased life expectancy for patients affected by CLL. However, mortality and morbidity
-
Acute Myeloid Leukemia Treatment in the Elderly: A Comprehensive Review of the Present and Future. Acta Haematol. (IF 2.4) Pub Date : 2023-07-17 Jun Choi,Mihir Shukla,Maher Abdul-Hay
BACKGROUND Acute myeloid leukemia (AML) is a disease of the hematopoietic system that remains a therapeutic challenge despite advances in our understanding of the underlying cancer biology in the past decade. It is also an affliction of the elderly that predominantly affects patients above 60 years of age. Standard therapy involves intensive chemotherapy that is often difficult to tolerate in older
-
Photon Counting Detector Computed Tomography: A New Frontier of Myeloma Bone Disease Evaluation. Acta Haematol. (IF 2.4) Pub Date : 2023-06-20 Joselle Cook,Kishore Rajendran,Andrea Ferrero,Preet Dhillon,Shaji Kumar,Francis Baffour
Photon counting detector (PCD) computed tomography (CT) is a paradigm-shifting innovation in CT imaging which was recently granted approval for clinical use by the US Food and Drug Administration. PCD-CT allows the generation of multi-energy images with increased contrast and scanning speed or ultra-high spatial resolution (UHR) images with lower radiation doses, compared to the currently used energy
-
Transient Daratumumab-Induced Refractive Shift in Multidrug-Resistant Multiple Myeloma: Case Report and Literature Review. Acta Haematol. (IF 2.4) Pub Date : 2023-06-16 Salvatore Troisi,Valentina Giudice,Mario Troisi,Denise Morini,Andrea Crudele,Bianca Cuffa,Carmine Selleri,Bianca Serio
Daratumumab, an anti-CD38 monoclonal antibody, is worldwide approved for treatment of newly diagnosed and relapsed/refractory multiple myeloma (MM) patients and is available as intravenous or subcutaneous formulations. Intravenous daratumumab is associated with frequent infusion-related reactions, while eye complications, especially refractive shifts, are very rare, with only previously reported cases
-
Adverse Effects of COVID-19 Vaccination in Patients with Transfusion-Dependent Thalassemia: An Observational Study from a Tertiary Care Center in Punjab, India. Acta Haematol. (IF 2.4) Pub Date : 2023-06-16 Shruti Kakkar,Evani Jain,Anirudh Jain,Priyanka Dewan
Vaccination against SARS-CoV-2 is the most important weapon in the arsenal in the battle against COVID-19. There is concern about an increased risk of adverse effects in patients with transfusion-dependent thalassemia (TDT), which affects vaccine acceptance. A predesigned questionnaire was used to evaluate adverse effects (local/systemic within 90 days after vaccination) in participants >18 years of
-
Impact of Geographical Distance from Quaternary Treatment Center on Clinical Trial Participation, Intensive Induction Chemotherapy, and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia. Acta Haematol. (IF 2.4) Pub Date : 2023-06-14 Samantha A Hershenfeld,Eshetu G Atenafu,Steven Chan,Vikas Gupta,Dawn Maze,Andre Schuh,Hassan Sibai,Karen Yee,Arron D Schimmer
INTRODUCTION Care for patients with acute myeloid leukemia (AML) is centralized in the Ontario single-payer public healthcare system, with intensive induction chemotherapy and clinical trials only offered at specialized cancer centers with large catchment areas. METHODS We therefore conducted a retrospective single-center review of all AML patients assessed at a large specialized cancer center in Ontario
-
False-Negative Testing for FIP1L1::PDGFRA by Fluorescence in situ Hybridization Is a Frequent Cause of Diagnostic Delay. Acta Haematol. (IF 2.4) Pub Date : 2023-06-07 Thanai Pongdee,Alexis Berry,Lauren Wetzler,Xiaoping Sun,Lauren Thumm,Pryscilla Yoon,Fei Li Kuang,Michelle Makiya,Gregory Constantine,Paneez Khoury,Esther Rheinbay,Andrew A Lane,Irina Maric,Amy D Klion
The imatinib-sensitive fusion gene FIP1L1::PDGFRA is the most frequent molecular abnormality identified in patients with eosinophilic myeloid neoplasms. Rapid recognition of this mutation is essential given the poor prognosis of PDGFRA-associated myeloid neoplasms prior to the availability of imatinib therapy. We report a case of a patient in whom delayed diagnosis resulted in cardiac transplantation
-
Pregnancy Course of 10 Women Diagnosed with Chronic Lymphocytic Leukemia. Acta Haematol. (IF 2.4) Pub Date : 2023-06-05 Tamar Tadmor,Guy Melamed,Hillel Alapi,Sivan Gazit,Tal Patalon,Lior Rokach
Pregnancies following diagnosis of chronic lymphocytic leukemia (CLL) are rare events, mainly because the disease is typically diagnosed in the elderly. Literature on the topic is based only on case reports, and limited data are available on the influence of pregnancy on CLL course. In this retrospective study, we aimed to summarize the clinical and laboratory course of 10 women with CLL who became
-
Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study. Acta Haematol. (IF 2.4) Pub Date : 2023-05-19 Moshe Mittelman,Uwe Platzbecker,Sebastian Grosicki,Tomasz Lawniczek,Zewen Zhu,Dominik Selleslag
ASPIRE, a three-part, international, phase 2 trial (ClinicalTrials.gov identifier: NCT01440374), investigated eltrombopag efficacy and safety in patients with advanced myelodysplastic syndrome or acute myeloid leukemia and grade 4 thrombocytopenia (<25 × 109 platelets/L). Approximately 30-65% of patients in this open-label extension phase experienced clinically relevant thrombocytopenic events; no
-
The Recurrent Atypical e8a2 BCR::ABL1 Transcript with Insertion of an Inverted 55 Base Pair ABL1 Intron 1b Sequence: A Detailed Molecular Analysis. Acta Haematol. (IF 2.4) Pub Date : 2023-05-19 Thomas Burmeister,Lars Bullinger,Philipp le Coutre
Atypical BCR::ABL1 transcripts are found in approximately 2% of cases of chronic myeloid leukemia. It is important to detect them since affected patients also benefit from tyrosine kinase inhibitor therapy. In the rare e8a2 atypical BCR::ABL1 transcript, two out-of-frame exons are fused, thus, interposed nucleotides are usually found at the fusion site to restore the reading frame. In approximately
-
Acute Myeloid Leukemia with NPM1 Mutation and Disseminated Leukemia Cutis: Achievement of Molecular Complete Remission by Venetoclax/Azacitidine Combination in a Very Old Patient. Acta Haematol. (IF 2.4) Pub Date : 2023-05-17 Pasquale Niscola,Carla Mazzone,Stefano Fratoni,Nicolina Rita Ardu,Laura Cesini,Marco Giovannini,Tiziana Ottone,Lucia Anemona,Maria Teresa Voso,Paolo de Fabritiis
We describe a case of acute myeloid leukemia with NPM1 mutation and disseminated leukemia cutis in a very old patient, who achieved a long-lasting response to the azacitidine/venetoclax combination with molecular complete remission, given the potential value of this rarely observed clinical outcome.
-
Utility of Galactomannan Screening for Early Detection of Invasive Aspergillosis in High-Risk Hemato-Oncology Patients. Acta Haematol. (IF 2.4) Pub Date : 2023-05-17 Rozan Sabbah,Maya Korem,Adir Shaulov,Shlomzion Aumann,Boaz Nachmias
INTRODUCTION Invasive aspergillosis (IA) affects mainly patients with hematological malignancies, and early diagnosis is crucial for timely treatment. Most diagnoses are based on clinical and mycological criteria, mostly galactomannan (GM) test in serum or bronchoalveolar fluid, which is performed in case of clinical suspicion or as routine screening in patients at high risk who are not receiving anti-mold
-
Prognostic Significance of CD20 Expression in Children with Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia. Acta Haematol. (IF 2.4) Pub Date : 2023-05-07 Yu Wang,Yu-Juan Xue,Yue-Ping Jia,Ying-Xi Zuo,Ai-Dong Lu,Le-Ping Zhang
INTRODUCTION The prognostic significance of CD20 in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) remains unclear. Therefore, in this study, we evaluated the prognostic value of CD20 expression in leukemia blasts in pediatric BCP-ALL at our institute. METHODS Between 2005 and 2017, 796 children with newly diagnosed Philadelphia-negative BCP-ALL were enrolled consecutively; clinical
-
Impact of Prophylactic Antibacterials on Coagulation Profiles and Bleeding in Patients with Acute Myeloid Leukemia/Myelodysplastic Syndrome Acta Haematol. (IF 2.4) Pub Date : 2023-04-26 Cecily Allen, Samir Gautam, Wei Cheng, Alexander B. Pine, Nikolai A. Podoltsev, Amer M Zeidan, Alfred I Lee, Rory M. Shallis
Patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) often receive antibacterial prophylaxis. Antibacterial agents can cause elevations in the prothrombin time and international normalized ratio (INR). The impact of prophylactic antibacterials on the coagulation profiles and bleeding risk in patients with AML/MDS is unknown. We evaluated patients with AML or MDS who were being
-
Recapitulated late-onset inflammatory toxicities and progressive dysautonomia with persistence of central memory CD4+ chimeric antigen receptor T cells in a case of transformed follicular lymphoma: case report Acta Haematol. (IF 2.4) Pub Date : 2023-04-21 Mitsutaka Nishimoto, Teruhito Takakuwa, Masatomo Kuno, Yosuke Makuuchi, Hiroshi Okamura, Yasuhiro Nakashima, Hideo Koh, Hiroto Namba, Yoshiaki Itoh, Masayuki Hino, Hirohisa Nakamae
CD19-directed chimeric antigen receptor (CAR) T-cell therapy has been widely used and highly effective for B-cell lymphoid malignancies. Immune-mediated adverse effects such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) occur in the acute phase and are monophasic after CAR T-cell therapy. However, late-onset inflammatory and neurological toxicities
-
Prediction of Splenectomy Outcomes in Relapsed or Refractory Immune Thrombocytopenia Acta Haematol. (IF 2.4) Pub Date : 2023-04-21 Philip Murphy
A recent publication by Kwag et al suggests that first line response to intravenous immunoglobulins in patients with immune thrombocytopenia (ITP) may predict long term response to splenectomy. Predominant platelet sequestration using platelet kinetic studies may similarly predict ITP patients who respond rest to splenectomy. A study comparing response to intravenous immunoglobulins and platelet kinetic
-
Multicentric Castleman disease and concurrent hematological disorders: the occurrence of plasmacytoma and the hypotheses arising from literature’s review Acta Haematol. (IF 2.4) Pub Date : 2023-04-17 Andrea Duminuco, Alessandra Romano, Elena Sabattini, Loredana Villari, Vittorio Del Fabro, Federica Elia, Giuseppe A. Palumbo, Francesco Di Raimondo, Concetta Conticello
The concomitant presence of Castleman disease with other hematological pathology is an event described in the literature with increasing frequency, able to modify the diagnostic and curative approach in such patients. Very few studies in the literature describe the association of CD with concomitant neoplastic diseases: the most frequent are Kaposi’s sarcomas (especially in HIV and HHV-8 positive patients)
-
An Analysis of Dasatinib Treatment Patterns in Patients with Chronic Myeloid Leukemia After Experiencing Pleural Effusion During Dasatinib Therapy Acta Haematol. (IF 2.4) Pub Date : 2023-04-10 Ali McBride, John Brokars, Sheila Reiss Reddy, Eunice Chang, Marian H. Tarbox, Thomas W. LeBlanc
Introduction: Treatment with dasatinib for chronic myeloid leukemia (CML) has been associated with development of pleural effusion, however data regarding its optimal management are limited. We examined treatment patterns and healthcare resource utilization (HCRU) and costs among patients with CML treated with dasatinib who experienced a subsequent pleural effusion. Methods: Adults with CML and ≥1